Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9BREJ)

Drug Name

MYK-491 Drug Info

Synonyms

Danicamtiv; UNII-7B2CS922HI; 7B2CS922HI; SAR440181; 1970972-74-7; Danicamtiv [INN]; Danicamtiv [USAN]; Danicamtiv (USAN/INN); MYK491; CHEMBL4594304; SCHEMBL17942536; WHO 10942; SAR-440181; HY-109128; CS-0086762; D11824; (R)-4-(1-((3-(Difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide; 1-Piperidinecarboxamide, 4-((1R)-1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-3-isoxazolyl-

Indication

Disease Entry	ICD 11	Status	REF
Dilated cardiomyopathy	BC43.0	Phase 2	[1]

Cross-matching ID

PubChem CID: 122424426
CAS Number: CAS 1970972-74-7
TTD Drug ID: DM9BREJ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Myosin (MYO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mavacamten	DMK9BP2	Obstructive hypertrophic cardiomyopathy	BC43.12	Approved	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Myosin (MYO)	TTITSMB	NOUNIPROTAC	Activator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03447990) Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491. U.S. National Institutes of Health.
2	Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020 Sep;22(9):1649-1658.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)